Reprehenderit in voluptate velit esse cillum dolore

Revolutionizing Inflammation Treatment with Innovative Oral Medicines and Cutting-Edge RBP Technology

Trotana is a biotechnology company developing novel oral anti-inflammatory medicines to clinically-validated mechanisms.  Our experienced team is passionate about creating shareholder value by advancing novel therapeutic options for patients suffering with inflammatory diseases.

The company’s strategic advantages include our deep understanding of RNA binding protein (RBP) biology and small molecule drug discovery targeting RBPs.   Our proprietary platform, referred to as our RNA binding protein modulator engine (RiME), has successfully generated orally-dosed therapeutics targeting the human RBPs and is being utilized to expand our proprietary pipeline.

We prioritize RBP targets that control expression of known disease-driving inflammatory proteins and control immune cell fate in patients living with inflammation.